The 2025 estimates side by side
Three published figures cover the same market year with different scopes. Grand View Research’s in vitro diagnostics industry report (accessed November 2026) values the 2025 market at USD 107.4 billion, rising to USD 112.5 billion in 2026 and USD 163.0 billion by 2033 at a 5.4% CAGR (2026–2033). Kalorama Information’s 19th edition of The Worldwide Market for In Vitro Diagnostic Tests (published September 4, 2025) reports US$115.6 billion for 2025 with US$150.4 billion projected by 2030. MarketsandMarkets’ published abstract cites roughly USD 104 billion for 2025. The estimates agree on direction and rough scale; they disagree on where the boundary of "the market" sits.
Why the numbers differ: scope, not error
Market-size disagreements are almost always definition disagreements. One estimate counts only regulated IVD consumables; another adds research-use-only reagents, which are a large business adjacent to clinical diagnostics. Self-test and over-the-counter products sit inside some definitions and outside others. Instruments and service contracts may be counted once, amortized, or excluded. An earlier Kalorama edition working with a broader definition reported USD 124 billion, while Kalorama’s own 2023 market overview reported USD 106 billion — same publisher, same market, different scope. When a page quotes a single number without scope and date, it is hiding the only two facts that make the number interpretable.
What converges: the 2030 projection
Despite the different 2025 baselines, the major projections land in the same place: roughly US$150 billion by 2030, at 5.4–5.6% annual growth. Kalorama reaches US$150.4 billion by 2030; Grand View Research passes through a comparable trajectory to USD 163.0 billion by 2033. For planning purposes, the defensible statement is "mid-single-digit annual growth to about US$150 billion by 2030" — not any single starting point.
What this means for IVD buyers
For a laboratory or distributor, segment size is context for supplier behavior, not a selection criterion. A large and growing segment means active vendor competition and more new-product announcements; it does not change whether a specific assay is registered in your market, whether the manufacturer services your country, or what the reagent contract costs per test. Those are answerable only per supplier and per product — which is the layer IVDmap’s product and company records work at, with each published specification traced to its source page.
How this page is kept honest
Every figure above carries its publisher, edition or report name, and publication or access date. Where a number could not be independently re-verified by IVDmap, it is attributed to the publisher’s own published abstract and linked. This page is dated November 2026; estimates are revised annually by their publishers, and figures should always be read together with their scope statement, never alone.
